Skip to content

Clinical efficacy observation of Gushang Liniment in the treatment of joint and soft tissue injuries

Clinical efficacy observation of Gushang Liniment in the treatment of joint and soft tissue injuries

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001294
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint and soft tissue injuries

Interventions

Gushang Liniment group:At 48 hours post-injury Gushang Liniment (dosage adjusted per lesion size) was applied topically to the affected site every 10 minutes (3–4 times daily) alongside standard care.
Conventional treatment group:Oral imrecoxib (0.1 g/capsule BID).
Jingushang Spray group:At 48 hours post-injury Jingushang Spray (dosage adjusted per lesion size) was applied topically to the affected site every 10 minutes (3–4 times daily) alongside standard care.

Sponsors

the 71st Group Army Hospital of the Chinese PLA Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients meeting the diagnostic criteria for limb soft tissue injuries including sprains of the knee ankle and wrist joints presenting with localized pain swelling and restricted range of motion. Eligible participants were aged 18–60 years with no prior use of oral or topical pharmacotherapy or alternative treatments. Exclusion of individuals with neurovascular impairment cardiovascular hepatic renal or hematopoietic disorders as well as psychiatric conditions tuberculosis or malignancies. All participants provided written informed consent prior to enrollment.

Exclusion criteria

Exclusion criteria: Exclusion criteria comprised: age 60 years; history of severe cardiac hepatic splenic pulmonary or renal dysfunction; pregnancy or lactation; non-adherence to prescribed treatment regimens; inability to assess efficacy due to incomplete data or confounding factors; occurrence of severe adverse events (SAEs) complications or physiological alterations necessitating trial discontinuation; voluntary withdrawal or premature termination of treatment or follow-up assessments.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy;

Secondary

MeasureTime frame
Bruising elimination time;White blood cell differential;Mobility status;White blood cell (WBC) count;Red blood cell (RBC) count;Serum c-reactive protein (CRP) level;Joint function grading;Bruising severity;Pain score (NRS);Swelling severity;Pain elimination time;Swelling elimination time;Platelet count;Serum erythrocyte sedimentation rate (ESR);

Countries

China

Contacts

Public ContactYang Yang

the 71st Group Army Hospital of the Chinese PLA Army

newyyang@163.com+86 187 9542 5217

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026